Allergan Biocell textured breast implants

In July 2019 the US Food and Drug Administration (FDA) requested that Allergan recall its Allergan Natrelle BIOCELL Textured Breast Implants and Tissue Expanders, from sale worldwide. Allergan agreed and a global recall of the products followed.


The FDA acted based on growing data that Allergan Implants are linked with patients developing a rare type of non-Hodgkin’s lymphoma described as Breast Implant Associated Anaplastic Large Cell Lymphoma, or BIA-ALCL

Recalled products list

Action in the Netherlands

On 1 December 2021, on behalf of the Dutch women’s rights organization Bureau Clara Wichmann, Hausfeld Advocaten in Amsterdam held Allergan liable and requested that it compensate all damages suffered by women in the Netherlands with Allergan biocell breast implants. As Allergan refused, a collective action on behalf of Bureau Clara Wichmann grouping the 60.000 women in the Netherlands who received Allergan biocell breast implants was filed on 12 December 2022. This lawsuit is an initiative of Bureau Clara Wichmann with the support of Stichting SVS/Meldpunt Klachten Siliconen and the Breast Cancer Association of the Netherlands.

For those affected in the Netherlands, the dedicated Dutch claim website 'Siliconen Zaak' offers additional information. 


The Guardian
BNR Nieuwsradio